Oxyntomodulin increases intrinsic heart rate through the glucagon receptor

Physiological Reports

Volumn 1, Issue 5, 2013, Pages

  Mukharji, Auyon ^a   Drucker, Daniel J ^b   Charron, Maureen J ^c   Swoap, Steven J ^a  

^a WILLIAMS COLLEGE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Beta block; GLP 1; OXM; Sympathetic nervous system

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ; GHRELIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; LEPTIN; METHACHOLINE; METHOXAMINE; METOPROLOL; MUSCARINIC RECEPTOR; OXYNTOMODULIN; PEPTIDE YY [3-36];

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; ENVIRONMENTAL TEMPERATURE; FEMALE; GENE EXPRESSION REGULATION; GENOTYPING TECHNIQUE; HEART RHYTHM; MOUSE; NONHUMAN; PARASYMPATHETIC TONE; POLYMERASE CHAIN REACTION; PRESSORECEPTOR REFLEX; PROTEIN EXPRESSION; RESTING HEART RATE; SIGNAL TRANSDUCTION; TELEMETRY;

EID: 85009067362     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.112     Document Type: Article

References (50)

1. Baggio, L. L., Q. Huang, T. J. Brown, and D. J. Drucker. 2004. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546–558.
2. Belardinelli, L., J. Shryock, Y. Song, D. Wang, and M. Srinivas. 1995. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J. 9: 359–365.
3. Burcelin, R., J. Li, and M. J. Charron. 1995. Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Gene 164: 305–310.
4. Chaudhri, O. B., V. Salem, K. G. Murphy, and S. R. Bloom. 2008. Gastrointestinal satiety signals. Annu. Rev. Physiol. 70: 239–255.
5. Cohen, M. A., S. M. Ellis, C. W. le Roux, R. L. Batterham, A. Park, M. Patterson, et al. 2003. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88: 4696–4701.
6. Conarello, S., G. Jiang, J. Mu, Z. Li, J. Woods, E. Zycband, et al. 2007. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50: 142–150.
7. Cryer, P. E. 2012. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153: 1039–1048.
8. Cummings, D. E., and J. Overduin. 2007. Gastrointestinal regulation of food intake. J. Clin. Invest. 117: 13–23.
9. Dakin, C. L., I. Gunn, C. J. Small, C. M. B. Edwards, D. L. Hay, D. M. Smith, et al. 2001. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142: 4244–4250.
10. Dakin, C. L., C. J. Small, R. L. Batterham, N. M. Neary, M. A. Cohen, M. Patterson, et al. 2004. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687–2695.
11. De Angelis, K., R. B. Wichi, W. R. A. Jesus, E. D. Moreira, M. Morris, E. M. Krieger, et al. 2004. Exercise training changes autonomic cardiovascular balance in mice. J. Appl. Physiol. 96: 2174–2178.
12. DeWitt, C. R., and J. C. Waksman. 2004. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol. Rev. 23: 223–238.
13. Druce, M. R., and M. Ghatei. 2006. Oxyntomodulin. Curr. Opin. Endocrinol. Diabetes 13: 49–55.
14. Druce, M. R., C. J. Small, and S. R. Bloom. 2004. Minireview: gut peptides regulating satiety. Endocrinology 145: 2660–2665.
15. Drucker, D. J. 2007. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117: 24–32.
16. Dunphy, J. L., R. G. Taylor, and P. J. Fuller. 1998. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol. 141: 179–186.
17. Foley, C. M., R. M. McAllister, and E. M. Hasser. 2001. Thyroid status influences baroreflex function and autonomic contributions to arterial pressure and heart rate. Am. J. Physiol. Heart Circ. Physiol. 280: H2061–H2068.
18. Gelling, R. W., X. Q. Du, D. S. Dichmann, J. Romer, H. Huang, L. Cui, et al. 2003. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. PNAS 100: 1438–1443.
19. Gluck, E. F., N. Stephens, and S. J. Swoap. 2006. Peripheral ghrelin deepens torpor bouts in mice through the arcuate nucleus neuropeptide Y signaling pathway. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291: R1303–R1309.
20. Habegger, K. M., K. M. Heppner, N. Geary, T. J. Bartness, R. Dimarchi, and M. H. Tschop. 2010. The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6: 689–697.
21. Hansen, L. H., N. Abrahamsen, and E. Nishimura. 1995. Glucagon receptor mRNA distribution in rat tissues. Peptides 16: 1163–1166.
22. Heppner, K. M., K. M. Habegger, J. Day, P. T. Pfluger, D. Perez-Tilve, B. Ward, et al. 2010. Glucagon regulation of energy metabolism. Physiol. Behav. 100: 545–548.
23. Jones, B. J., T. Tan, and S. R. Bloom. 2012. Minireview: glucagon in stress and energy homeostasis. Endocrinology 153: 1049–1054.
24. Karra, E., and R. L. Batterham. 2010. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol. Cell. Endocrinol. 316: 120–128.
25. Kerns, W. 2007. Management of b-adrenergic blocker and calcium channel antagonist toxicity. Emerg. Med. Clin. North Am. 25: 309–331.
26. Kurosawa, M., S. Iijima, A. Funakoshi, T. Kawanami, K. Miyasaka, V. Bucinskaite, et al. 2001. Cholecystokinin-8 (CCK-8) has no effect on heart rate in rats lacking CCK-A receptors. Peptides 22: 1279–1284.
27. Longuet, C., E. M. Sinclair, A. Maida, L. L. Baggio, M. Maziarz, M. J. Charron, et al. 2008. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 8: 359–371.
28. Macneil, D. J., J. L. Occi, P. J. Hey, C. D. Strader, and M. P. Graziano. 1994. Cloning and expression of a human glucagon receptor. Biochem. Biophys. Res. Commun. 198: 328–334.
29. Maida, A., J. A. Lovshin, L. L. Baggio, and D. J. Drucker. 2008. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances b-cell function but does not inhibit gastric emptying in mice. Endocrinology 149: 5670–5678.
30. Mayo, K. E., L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, et al. 2003. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55: 167–194.
31. Murphy, K. G., and S. R. Bloom. 2006. Gut hormones and the regulation of energy homeostasis. Nature 444: 854–859.
32. Newton, C. R. H., J. H. Delgado, and H. F. Gomez. 2002. Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management. Semin. Respir. Crit. Care Med. 23: 19–25.
33. Palatini, P., E. Casiglia, P. Pauletto, J. Staessen, N. Kaciroti, and S. Julius. 1997. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 30: 1267–1273.
34. Parker, J. C., K. M. Andrews, M. R. Allen, J. L. Stock, and J. D. McNeish. 2002. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290: 839–843.
35. Parkinson, J. R. C., W. S. Dhillo, C. J. Small, O. B. Chaudhri, G. A. Bewick, I. Pritchard, et al. 2008. PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones. Am. J. Physiol. Endocrinol. Metab. 294: E698–E708.
36. Pocai, A. 2012. Unraveling oxyntomodulin, GLP1’s enigmatic brother. J. Endocrinol. 215: 335–346.
37. Shepard, G. 2006. Treatment of poisoning caused by b-adrenergic and calcium-channel blockers. Am. J. Health Syst. Pharm. 63: 1828–1835.
38. Sorensen, H., M. S. Winzell, C. L. Brand, K. Fosgerau, R. W. Gelling, E. Nishimura, et al. 2006. Glucagon receptor knockout mice display increased insulin sensitivity and impaired {beta}-cell function. Diabetes 55: 3463–3469.
39. Sowden, G. L., D. J. Drucker, D. Weinshenker, and S. J. Swoap. 2007. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292: R962–R970.
40. Steiner, C., A. L. Wit, and A. N. Damato. 1969. Effects of glucagon on atrioventricular conduction and ventricular automaticity in dogs. Circ. Res. 24: 167–177.
41. Stuesse, S. L., M. N. Levy, and H. Zieske. 1982. Effects of glucagon on cardiac chronotropic response to vagal stimulation in the dog. Am. J. Physiol. Heart Circ. Physiol. 242: H7–H12.
42. Swoap, S. J., C. Li, J. Wess, A. D. Parsons, T. D. Williams, and J. M. Overton. 2008. Vagal tone dominates autonomic control of mouse heart rate at thermoneutrality. Am. J. Physiol. Heart Circ. Physiol. 294: H1581–H1588.
43. Taboulet, P., A. Cariou, A. Berdeaux, and C. Bismuth. 1993. Pathophysiology and management of self-poisoning with beta-blockers. J. Toxicol. Clin. Toxicol. 31: 531–551.
44. Takayama, K., K.-I. Yuhki, K. Ono, T. Fujino, A. Hara, T. Yamada, et al. 2005. Thromboxane A2 and prostaglandin F2[alpha] mediate inflammatory tachycardia. Nat. Med. 11: 562–566.
45. Vuguin, P. M., and M. J. Charron. 2011. Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes. Metab. 13: 144–150.
46. Vuguin, P. M., M. H. Kedees, L. Cui, Y. Guz, R. W. Gelling, M. Nejathaim, et al. 2006. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 147: 3995–4006.
47. Watson, W. A., T. L. Litovitz, G. C. Rodgers, W. Klein-Schwartz, N. Reid, J. Youniss, et al. 2005. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 23: 589–666.
48. Williams, T. D., J. B. Chambers, R. P. Henderson, M. E. Rashotte, and J. M. Overton. 2002. Cardiovascular responses to caloric restriction and thermoneutrality in C57BL/6J mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282: R1459–R1467.
49. Wynne, K., A. J. Park, C. J. Small, M. Patterson, S. M. Ellis, K. G. Murphy, et al. 2005. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54: 2390–2395.
50. Wynne, K., A. J. Park, C. J. Small, K. Meeran, M. A. Ghatei, G. S. Frost, et al. 2006. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. 30: 1729–1736.